AI Decision Support Systems: FDA's Four Tests for Clinical Tools

Software must meet all four criteria to avoid device status: no images or signals, medical information, clinician recommendations, and reviewable basis.

Guide: AI Tools and IndustryLast verified: October 20265 min read

An AI decision support system gives a person a recommendation, and the person makes the decision. In U.S. health care, the Food and Drug Administration (FDA) decides whether such software is regulated as a medical device using four criteria from section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act, explained in a guidance document issued on January 29, 2026. The guidance turns on one idea: a clinician must be able to review the basis of a recommendation instead of simply following it.

Key takeaways

  • Software meets the non-device exclusion only if it satisfies all four statutory criteria, which cover its inputs, its information, its recommendations, and the clinician's ability to review the basis for them.
  • Software that gives a specific diagnostic or treatment directive, or that analyzes medical images or signals, stays a device.
  • FDA does not consider software for a critical, time-sensitive task or decision to meet the fourth criterion, because the clinician is unlikely to have time to review the basis.
  • Software aimed at patients or caregivers, not health care professionals, meets the definition of a device under this guidance.
  • The guidance contains nonbinding recommendations and covers the United States only.

Decision support versus automated decision

A decision support system presents analysis or advice to a human decision maker. An automated decision system acts without that person's judgment. The boundary matters in health care because the law treats the first kind of software more lightly, provided the person stays in charge. The 21st Century Cures Act added section 520(o)(1)(E) to the Federal Food, Drug, and Cosmetic Act to exclude certain clinical decision support (CDS) software from the device definition. The FDA guidance on clinical decision support software states the agency's interpretation of that provision. The January 29, 2026 document supersedes a version issued on January 6, 2026.

The four criteria

CriterionWhat the software must doWhat keeps it a device
One: inputsNot acquire, process, or analyze a medical image, a signal from an in vitro diagnostic device, or a pattern or signal from a signal acquisition systemAnalyzing an image or a physiological signal
Two: informationDisplay, analyze, or print medical information about a patient or other medical information, such as clinical studies and practice guidelinesInputs of a type outside that definition
Three: recommendationsSupport or provide recommendations to a health care professional about prevention, diagnosis, or treatmentA specific preventive, diagnostic, or treatment output or directive
Four: review of the basisLet the professional independently review the basis, so that the professional does not rely primarily on a recommendationTime-critical use or too little information to review

All four must be met. The guidance gives paired examples. Software that predicts the risk of a future cardiovascular event from weight, smoking status, blood pressure, and a lab test can fit, while the same software predicting a cardiovascular event in the next 24 hours does not fall under that example.

What "basis for the recommendation" means in practice

For the fourth criterion, the guidance recommends that the software or its labeling state the intended use, the intended health care professional, and the patient population. It should identify the required input information and how to obtain it. It should also give a plain-language description of how the algorithm was developed and validated, including the general approach (the guidance lists meta-analysis, expert panel, statistical modeling, and AI or machine learning), the data used so a clinician can judge whether it represents their patients, and the results of clinical validation studies. The output should show patient-specific information and what is known and unknown, such as missing or unexpected input values.

The guidance adds that this applies regardless of how complex or proprietary the software is, and that developers may need usability testing to show a clinician can use the information.

Automation bias and time pressure

The guidance defines automation bias as the propensity of humans to over-rely on a suggestion from an automated system. In clinical decision support it can cause errors of commission, where incorrect advice is followed, or errors of omission, where a clinician fails to act because the software did not prompt it. FDA states that in situations requiring urgent action, automation bias increases because there is not enough time to consider other information.

This reasoning explains the rule for time-critical tasks. Software intended for a critical, time-sensitive decision is not considered to meet the fourth criterion, and software that replaces or directs a clinician's judgment fails the third.

One recommendation, and software for patients

If only one option is clinically appropriate and the software otherwise meets all the criteria, FDA says it intends to exercise enforcement discretion, meaning it does not intend to enforce requirements under the Act for that function. Software that supports or provides recommendations to patients or caregivers, rather than professionals, meets the definition of a device. FDA says it intends to be consistent with its existing policies in regulating such software.

Questions for any clinical AI recommendation tool

  • Is the output a list of options and supporting information, or a single directive?
  • Does it analyze images or physiological signals?
  • Who is the intended user: a clinician or a patient?
  • Does the labeling describe the data and validation behind the recommendation?
  • Is the decision time-critical?

This page is general information about a regulatory document, not medical or legal advice. Clinical choices belong with a licensed professional, and a company deciding how its own product is classified should consult the guidance itself and qualified regulatory counsel.

FAQ

Is every AI decision support tool regulated by FDA?

No. Software that meets all four criteria is excluded from the device definition. Software that fails any one of them can remain a device.

Does the guidance have the force of law?

The document is labeled as containing nonbinding recommendations. The statutory criteria it interprets are part of federal law.

Does the guidance cover Canada?

No. It is a U.S. FDA document. Canadian rules for medical device software, issued by Health Canada, are a separate framework that this page does not describe.

Can a clinician simply follow the software?

For software to qualify as non-device clinical decision support, it must be built so the clinician does not rely primarily on the recommendation and can review its basis.

Last verified: October 2026

Sources

  • Clinical Decision Support Software: Guidance for Industry and Food and Drug Administration Staff, U.S. Food and Drug Administration, January 29, 2026
  • Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act, as described in the guidance, 21st Century Cures Act, 2016

New to artificial intelligence?

Start with the basics, then follow the guides to tools, rules, and effects on society.

Start with AI Basics